Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brilacidin - Alfasigma/Innovation Pharmaceuticals

Next Previous
Drug Profile

Brilacidin - Alfasigma/Innovation Pharmaceuticals

Alternative Names: Brilacidin tetrahydrochloride; Brilacidin-Ocular; Brilacidin-OM; Brilacidin-Otic; Defensin-mimetic - Innovation Pharmaceuticals; HDP-mimic - Innovation Pharmaceuticals; Host defense protein-mimic - Innovation Pharmaceuticals; PMX-30063

Latest Information Update: 28 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PolyMedix
  • Developer Innovation Pharmaceuticals
  • Class Amides; Anti-infectives; Anti-inflammatories; Antiacnes; Antibacterials; Antivirals; Foot disorder therapies; Guanidines; Peptidomimetics; Pyrimidines; Pyrrolidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators; Immunomodulators; Type 4 cyclic nucleotide phosphodiesterase inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Phase II COVID 2019 infections; Skin and soft tissue infections; Stomatitis; Ulcerative proctitis
  • No development reported Acne; Alphavirus infections; Atopic dermatitis; Bunyavirus infections; Coronavirus infections; Diabetic foot ulcer; Ebola virus infections; Hidradenitis suppurativa; Inflammatory bowel diseases; Marburg virus disease; Nipah virus infections; Otitis; West Nile virus infections; Wounds; Zika virus infection
  • Discontinued Intestinal infections; Ophthalmic infections; Ulcerative colitis

Most Recent Events

  • 28 Nov 2025 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA
  • 28 Nov 2025 No recent reports of development identified for preclinical development in Marburg virus disease in USA
  • 28 Nov 2025 No recent reports of development identified for preclinical development in Nipah-virus-infections in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top